Positive News SentimentPositive NewsNASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free KRON Stock Alerts $0.79 +0.01 (+1.28%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.75▼$0.8050-Day Range$0.75▼$1.3852-Week Range$0.69▼$2.29Volume215,146 shsAverage Volume407,369 shsMarket Capitalization$47.47 millionP/E RatioN/ADividend YieldN/APrice Target$4.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kronos Bio alerts: Email Address Kronos Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside422.2% Upside$4.13 Price TargetShort InterestHealthy1.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.62) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector323rd out of 928 stocksPharmaceutical Preparations Industry146th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingKronos Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKronos Bio has only been the subject of 1 research reports in the past 90 days.Read more about Kronos Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.67% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kronos Bio has recently increased by 3.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKronos Bio does not currently pay a dividend.Dividend GrowthKronos Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRON. Previous Next 3.3 News and Social Media Coverage News SentimentKronos Bio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kronos Bio this week, compared to 1 article on an average week.Search Interest8 people have searched for KRON on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Kronos Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kronos Bio insiders have not sold or bought any company stock.Percentage Held by Insiders23.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kronos Bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kronos Bio are expected to grow in the coming year, from ($1.62) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kronos Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kronos Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKronos Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kronos Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only financial event in 2024 that matters Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral.Stream the documentary for free by clicking here About Kronos Bio Stock (NASDAQ:KRON)Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Read More KRON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRON Stock News HeadlinesMay 23, 2024 | globenewswire.comKronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2024 | globenewswire.comKronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsMay 21, 2024 | finanznachrichten.deKronos Bio, Inc.: Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial OfficerMay 21, 2024 | marketwatch.comKronos Bio Hires Ex-Senti Bio CFO to Head Finances, OperationsMay 21, 2024 | globenewswire.comKronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial OfficerMay 16, 2024 | msn.comDown -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a TurnaroundMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Kronos Bio Amid Positive KB-0742 Trial Progress and Expanding Oncology PipelineMay 10, 2024 | msn.comKronos Bio GAAP EPS of -$0.50 misses by $0.08, revenue of $2.52MMay 9, 2024 | msn.comKRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comKronos Bio Reports First-Quarter 2024 Financial ResultsMay 6, 2024 | seekingalpha.comKronos Bio: Underestimated Drug Discovery PlatformMay 5, 2024 | uk.investing.comKronos Bio shares target cut, retains buy ratingMay 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kronos Bio Amid Promising KB-0742 Data and Solid Financial FootingApril 30, 2024 | wsj.comKronos Bio Inc.April 24, 2024 | globenewswire.comKronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMarch 31, 2024 | msn.com5 Boutique Fitness Studios in Bangkok for an Elevated Workout ExperienceMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)March 21, 2024 | benzinga.comRecap: Kronos Bio Q4 EarningsMarch 21, 2024 | msn.comKronos Bio reports Q4 resultsMarch 21, 2024 | investorplace.comKRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comKronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | seekingalpha.comKRON Kronos Bio, Inc.March 8, 2024 | bizjournals.comCancer drug developer Kronos Bio slashes staffing for 2nd time in 4 monthsMarch 7, 2024 | marketwatch.comKronos Bio to Cut About 21% of WorkforceMarch 7, 2024 | globenewswire.comKronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwaySee More Headlines Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/02/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRON CUSIPN/A CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Target$4.13 High Stock Price Target$6.00 Low Stock Price Target$2.25 Potential Upside/Downside+422.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,670,000.00 Net Margins-1,534.11% Pretax Margin-1,534.11% Return on Equity-68.67% Return on Assets-52.03% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio8.32 Sales & Book Value Annual Sales$6.29 million Price / Sales7.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book0.35Miscellaneous Outstanding Shares60,090,000Free Float46,032,000Market Cap$47.47 million OptionableOptionable Beta1.85 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Norbert W. Bischofberger Ph.D. (Age 68)President, CEO & Director Comp: $912.2kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $40kMr. David M. Tanen J.D. (Age 53)Secretary & Director Comp: $40kMs. Sandra A. Gardiner (Age 58)Interim CFO & Principal Accounting Officer Dr. Margaux Bennett Ph.D.Vice President of Corporate Development & Investor RelationsMs. Allison Frisbee J.D. (Age 41)Senior Vice President of Corporate Operations & Legal Dr. Charles Lin Ph.D. (Age 39)Senior Vice President of Research & Development Dr. Elizabeth A. Olek D.O. (Age 59)M.P.H., Senior Vice President of Clinical Development Mr. Wes Trotter Ph.D.Senior Vice President of Drug Discovery & Pharmaceutical DevelopmentMs. Rocio Martin HoyosSenior Vice President of Corporate Strategy & Portfolio ManagementMore ExecutivesKey CompetitorsTrevi TherapeuticsNASDAQ:TRVIAtossa TherapeuticsNASDAQ:ATOSG1 TherapeuticsNASDAQ:GTHXGalectin TherapeuticsNASDAQ:GALTGreenwich LifeSciencesNASDAQ:GLSIView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 54,592 shares on 5/20/2024Ownership: 0.091%Jacobs Levy Equity Management Inc.Sold 234,132 shares on 5/16/2024Ownership: 0.099%Vanguard Group Inc.Bought 247,918 shares on 5/10/2024Ownership: 3.243%Acadian Asset Management LLCBought 113,618 shares on 5/10/2024Ownership: 1.289%Marquette Asset Management LLCBought 13,269 shares on 5/7/2024Ownership: 0.134%View All Insider TransactionsView All Institutional Transactions KRON Stock Analysis - Frequently Asked Questions Should I buy or sell Kronos Bio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRON shares. View KRON analyst ratings or view top-rated stocks. What is Kronos Bio's stock price target for 2024? 2 brokers have issued 12 month target prices for Kronos Bio's stock. Their KRON share price targets range from $2.25 to $6.00. On average, they predict the company's share price to reach $4.13 in the next year. This suggests a possible upside of 422.2% from the stock's current price. View analysts price targets for KRON or view top-rated stocks among Wall Street analysts. How have KRON shares performed in 2024? Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON shares have decreased by 36.8% and is now trading at $0.79. View the best growth stocks for 2024 here. When is Kronos Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our KRON earnings forecast. How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.07. The business earned $2.52 million during the quarter, compared to analysts' expectations of $1.50 million. Kronos Bio had a negative trailing twelve-month return on equity of 68.67% and a negative net margin of 1,534.11%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. Who are Kronos Bio's major shareholders? Kronos Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.24%), Acadian Asset Management LLC (1.29%), Marquette Asset Management LLC (0.13%), Jacobs Levy Equity Management Inc. (0.10%) and Virtu Financial LLC (0.09%). Insiders that own company stock include Backer Marianne De, Barbara Kosacz, Christopher Dinsmore, Elizabeth A Olek, Jorge Dimartino, Norbert W Bischofberger and Yasir B Al-Wakeel. View institutional ownership trends. How do I buy shares of Kronos Bio? Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRON) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
